Vytorin Won’t Be ENHANCEd By Part D In 2009: Formulary Review
Executive Summary
Three of the leading Medicare Part D sponsors will not cover Merck/Schering-Plough's Vytorin in their stand-alone drug plans in 2009, and much of the blame can probably be laid on the disappointing results of the ENHANCE study earlier this year
You may also be interested in...
Vytorin, Zetia Coverage In 2009 Among All Payers Still Solid But Slipping
Merck/Schering-Plough's cholesterol drugs Vytorin and Zetia will be reimbursed without restriction as preferred brands for about 67 percent of individuals enrolled in commercial and Medicare Part D plans in 2009, according to Merck
Vytorin, Zetia Coverage In 2009 Among All Payers Still Solid But Slipping
Merck/Schering-Plough's cholesterol drugs Vytorin and Zetia will be reimbursed without restriction as preferred brands for about 67 percent of individuals enrolled in commercial and Medicare Part D plans in 2009, according to Merck
FDA Changes Its Mind On Vytorin; Ads Must Note “Efficacy Limitation”
One of the more interesting revelations from the House Energy and Commerce Committee's investigation into the ENHANCE trial is a document that may help explain why the Vytorin TV ads were pulled - and how FDA is handling questions about product efficacy in the current environment